Literature DB >> 12374738

CD40 regulates the processing of NF-kappaB2 p100 to p52.

H J Coope1, P G P Atkinson, B Huhse, M Belich, J Janzen, M J Holman, G G B Klaus, L H Johnston, S C Ley.   

Abstract

The nf-kb2 gene encodes the cytoplasmic NF-kappaB inhibitory protein p100 from which the active p52 NF-kappaB subunit is derived by proteasome-mediated proteolysis. Ligands which stimulate p100 processing to p52 have not been defined. Here, ligation of CD40 on transfected 293 cells is shown to trigger p52 production by stimulating p100 ubiquitylation and subsequent proteasome-mediated proteolysis. CD40-mediated p52 accumulation is dependent on de novo protein synthesis and triggers p52 translocation into the nucleus to generate active NF-kappaB dimers. Endogenous CD40 ligation on primary murine splenic B cells also stimulates p100 processing, which results in the delayed nuclear translocation of p52-RelB dimers. In both 293 cells and primary splenic B cells, the ability of CD40 to trigger p100 processing requires functional NF-kappaB-inducing kinase (NIK). In contrast, NIK activity is not required for CD40 to stimulate the degradation of IkappaBalpha in either cell type. The regulation of p100 processing by CD40 is likely to be important for the transcriptional regulation of CD40 target genes in adaptive immune responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12374738      PMCID: PMC129074          DOI: 10.1093/emboj/cdf542

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  50 in total

Review 1.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 2.  CD40-CD154 interactions in B-cell signaling.

Authors:  D M Calderhead; Y Kosaka; E M Manning; R J Noelle
Journal:  Curr Top Microbiol Immunol       Date:  2000       Impact factor: 4.291

Review 3.  NF-kappaB at the crossroads of life and death.

Authors:  Michael Karin; Anning Lin
Journal:  Nat Immunol       Date:  2002-03       Impact factor: 25.606

4.  The generation of nfkb2 p52: mechanism and efficiency.

Authors:  M Heusch; L Lin; R Geleziunas; W C Greene
Journal:  Oncogene       Date:  1999-11-04       Impact factor: 9.867

5.  Abnormal immune function of hemopoietic cells from alymphoplasia (aly) mice, a natural strain with mutant NF-kappa B-inducing kinase.

Authors:  T Yamada; T Mitani; K Yorita; D Uchida; A Matsushima; K Iwamasa; S Fujita; M Matsumoto
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

6.  Immunodeficiency of alymphoplasia mice (aly/aly) in vivo: structural defect of secondary lymphoid organs and functional B cell defect.

Authors:  U Karrer; A Althage; B Odermatt; H Hengartner; R M Zinkernagel
Journal:  Eur J Immunol       Date:  2000-10       Impact factor: 5.532

7.  The death domain of NF-kappa B1 p105 is essential for signal-induced p105 proteolysis.

Authors:  Soren Beinke; Monica P Belich; Steven C Ley
Journal:  J Biol Chem       Date:  2002-04-25       Impact factor: 5.157

8.  TRAF2 deficiency results in hyperactivity of certain TNFR1 signals and impairment of CD40-mediated responses.

Authors:  L T Nguyen; G S Duncan; C Mirtsos; M Ng; D E Speiser; A Shahinian; M W Marino; T W Mak; P S Ohashi; W C Yeh
Journal:  Immunity       Date:  1999-09       Impact factor: 31.745

9.  A new mutation, aly, that induces a generalized lack of lymph nodes accompanied by immunodeficiency in mice.

Authors:  S Miyawaki; Y Nakamura; H Suzuka; M Koba; R Yasumizu; S Ikehara; Y Shibata
Journal:  Eur J Immunol       Date:  1994-02       Impact factor: 5.532

10.  Lineage-restricted function of nuclear factor kappaB-inducing kinase (NIK) in transducing signals via CD40.

Authors:  N Garceau; Y Kosaka; S Masters; J Hambor; R Shinkura; T Honjo; R J Noelle
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

View more
  149 in total

1.  Novel nonsense gain-of-function NFKB2 mutations associated with a combined immunodeficiency phenotype.

Authors:  Hye Sun Kuehn; Julie E Niemela; Karthik Sreedhara; Jennifer L Stoddard; Jennifer Grossman; Christian A Wysocki; M Teresa de la Morena; Mary Garofalo; Jingga Inlora; Michael P Snyder; David B Lewis; Constantine A Stratakis; Thomas A Fleisher; Sergio D Rosenzweig
Journal:  Blood       Date:  2017-08-04       Impact factor: 22.113

Review 2.  B cells: new ways to inhibit their function in rheumatoid arthritis.

Authors:  Robert H Carter
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

Review 3.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

Review 4.  Oncogenic activation of NF-kappaB.

Authors:  Louis M Staudt
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

5.  Constitutive CD40L expression on B cells prematurely terminates germinal center response and leads to augmented plasma cell production in T cell areas.

Authors:  Anna Bolduc; Eugene Long; Dale Stapler; Marilia Cascalho; Takeshi Tsubata; Pandelakis A Koni; Michiko Shimoda
Journal:  J Immunol       Date:  2010-05-26       Impact factor: 5.422

6.  Recruitment of RelB to the Csf2 promoter enhances RelA-mediated transcription of granulocyte-macrophage colony-stimulating factor.

Authors:  Carl Y Sasaki; Paritosh Ghosh; Dan L Longo
Journal:  J Biol Chem       Date:  2010-11-11       Impact factor: 5.157

7.  TRAF3 enforces the requirement for T cell cross-talk in thymic medullary epithelial development.

Authors:  S Rhiannon Jenkinson; Joy A Williams; Hyein Jeon; Jingjing Zhang; Takeshi Nitta; Izumi Ohigashi; Michael Kruhlak; Saulius Zuklys; Susan Sharrow; Anthony Adams; Larry Granger; Yongwon Choi; Ulrich Siebenlist; Gail A Bishop; Georg A Hollander; Yousuke Takahama; Richard J Hodes
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-09       Impact factor: 11.205

8.  Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation.

Authors:  Nagalakshmi Nadiminty; Wei Lou; Soo Ok Lee; Xin Lin; Donald L Trump; Allen C Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

9.  Specific NEMO mutations impair CD40-mediated c-Rel activation and B cell terminal differentiation.

Authors:  Ashish Jain; Chi A Ma; Eduardo Lopez-Granados; Gary Means; William Brady; Jordan S Orange; Shuying Liu; Steven Holland; Jonathan M J Derry
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 10.  Cell penetrating peptide inhibitors of nuclear factor-kappa B.

Authors:  J S Orange; M J May
Journal:  Cell Mol Life Sci       Date:  2008-11       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.